Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 8:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
GTS21/Placebo
Drug
Lead sponsor
CoMentis
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Durham, North Carolina
Conditions
Autism
Interventions
DMXB-A 150 mg, placebo, DMXB-A 75 mg
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Alzheimer Disease
Interventions
DMXB-A
Drug
Lead sponsor
CoMentis
Industry
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
280 South San Francisco, California
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Dimethoxybenzylidene anabaseine (DMXB-A), Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Denver, Colorado
Completed Phase 2 Interventional Results available

Nicotinic Receptors and Schizophrenia

NCT01400477
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
DMXB-A-SR, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Aurora, Colorado
Withdrawn Phase 1Phase 2 Interventional

Nicotinic Receptors and Schizophrenia

NCT02538081
Conditions
Schizophrenia
Interventions
Risperidone plus Placebo, Risperidone plus DMXB-A
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Completed Phase 2 Interventional Results available

Phase 2 Trial of a Nicotinic Agonist in Schizophrenia

NCT00100165
Conditions
Schizophrenia
Interventions
Placebo, 3-(2,4 dimethoxybenzylidene anabaseine) 150 mg, 3-(2,4 dimethoxybenzylidene anabaseine) 75 mg
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Nicotinic Agonist Effects on BMI and Neuronal Response

NCT02458313
Conditions
Obesity
Interventions
DMXB-A, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Denver, Colorado